Opinion statement
Esthesioneuroblastoma is a rare tumor for which the published literature does not provide an evidence-based consensus treatment approach. Multimodality therapy including a combination of surgery and radiation appears to provide the best disease-free and overall survival. Surgical resection should proceed through a craniofacial approach if possible. The role of chemotherapy in the initial treatment paradigm is less clear. Chemotherapy should not be used as single-modality therapy for initial treatment but may provide additional benefit when used in combination with radiation and surgery, particularly in advanced-stage disease. Combination chemotherapy should be considered as initial therapy for unresectable tumors and metastatic disease, and as salvage therapy in disease recurrence.
Similar content being viewed by others
References and Recommended Reading
Broich G, Pagliari A, Ottaviani F: Esthesioneuroblastoma:a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997, 17:2683–2706. Excellent review with historical perspective.
Lund AR, Howard D, Wei W, et al.: Olfactory neuroblastoma:past, present, and future? Laryngoscope 2003, 113:502–507.
Bradley PJ, Jones NS, Robertson I: Diagnosis and management of esthesioneuroblastoma. Curr Opin Otolaryngol Head Neck Surg 2003, 11:112–118. This is a comprehensive review incorporating recent advances and providing specific treatment algorithms.
Dulgerov P, Allal A, Calceterra T: Esthesioneuroblastoma:a meta-analysis and review. Lancet Oncol 2001, 2:683–690. A meta-analysis that highlights recent developments in diagnosis, staging, treatment, and outcomes in esthesioneuroblastoma.
Oskouian RJ, Jane JA, Dumont AS, et al.: Esthesioneuroblastoma:clinical presentation, radiological and pathological features, treatment, review of the literature, and the University of Virginia experience. Neurosurg Focus 2002, 12:1–9.
Hyams VJ, Batsakis JG, Micheals L:Tumors of the upper respiratory tract and ear. In Atlas of Tumor Pathology. Edited by Hyams VJ, Batsakis JG, Michaels L. Washington, DC:Armed Forces Institute of Pathology; 1998:240–248.
Kadish S, Goodman M, Wang CC: Olfactory neuroblastoma:a clinical analysis of 17 cases. Cancer 1976, 37:628–633.
Morita A, Ebersold MJ, Olsen KD, et al.: Esthesioneuroblastoma:prognosis and management. Neurosurgery 1993, 32:706–715.
Chamberlain MC: Treatment of intracranial metastatic esthesioneuroblastoma. Cancer 2002, 95:243–248.
Dulguerov P, Calcaterra T: Esthesioneuroblastoma:the UCLA experience 1970–1990. Laryngoscope 1992, 102:843–849.
Eden BV, Debo RF, Larner JM, et al.: Esthesioneuroblastoma. Cancer 1994, 73:2556–2562.
Dias LD, Sa GM, Lima RA, et al.: Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg 2003, 129:1186–1192.
Gruber G, Laedrach K, Baumert B, et al.: Esthesioneuroblastoma:irradiation alone and surgery alone are not enough. Int J Radiat Oncol Biol Phys 2002, 54:486–491.
Stieber VW, Munley M:Central nervous system tumors. In Intensity-Modulated Radiation Therapy (IMRT):A Clinical Perspective, edn 1. Edited by Mundt AJ, Roeske JC. Ontario, Canada:BC Decker Inc; 2005:231–263.
Zabel A, Thilman C, Zuna I, et al.: Comparison of forward planned conformal radiation therapy and inverse planned intensity modulated radiation therapy for esthesioneuroblastoma. Br J Radiol 2002, 75:356–361.
Unger F, Haselsberger K, Walch C, et al.: Combined endoscopic surgery and radiosurgery as treatment modality for olfactory neuroblastoma (esthesioneuroblastoma). Acta Neurochir (Wein) 2005, 147:595–602.
Sheehan JM, Sheehan JP, Jane JA, et al.: Chemotherapy for esthesioneuroblastomas. Neurosurg Clin N Am 2000, 11:693–701.
Mishima Y, Nagasaki E, Terui Y, et al.: Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with esthesioneuroblastoma. Cancer 2004, 101:1437–1444.
Fitzek MM, Thornton AF, Varvares M, et al.: Neuroendocrine tumors of the sinonasal tract. Cancer 2002, 94:2623–2634.
Eich HT, Hero B, Staar S, et al.: Multimodality therapy including radiotherapy and chemotherapy improves event free survival in stage C esthesioneuroblastoma. Strahlenther Onkol 2003, 179:233–240.
Theilgaard SA, Buchwald C, Ingeholm P, et al.: Esthesioneuroblastoma:a Danish demographics study of 40 patients registered between 1978 and 2000. Acta Otolaryngol 2003, 123:433–439.
Polin RS, Sheehan JP, Chenelle AG, et al.: The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma:the University of Virginia experience. Neurosurgery 1998, 42:1029–1037.
Diaz EM, Johnigan RH, Pero C, et al.: Olfactory neuroblastoma:the 22-year experience at one comprehensive cancer center. Head Neck 2005, 27:138–149.
Resto JA, Eisele DW, Forastiere A, et al.: Esthesioneuroblastoma:the Johns Hopkins experience. Head and Neck 2000, 22:550–558.
Kim D, Jo Y, Kim J, et al.: Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer 2004, 101:2257–2260.
Walch C, Stammberger H, Anderhuber W, et al.: The minimally invasive approach to olfactory neuroblastoma:combined endoscopic and stereotactic treatment. Laryngoscope 2000, 110:635–640.
Devaiah AK, Larsen C, Tawfik, et al.: Esthesioneuroblastoma:endoscopic nasal and anterior craniotomy resection. Laryngoscope 2003, 113:2086–2090.
Wick W, Wick A, Kuker W, et al.: Intracranial metastatic esthesioneuroblastoma responsive to temozolomide. J Neurooncol 2004, 70:73–75.
Constantinidis J, Steinhart H, Koch M, et al.: Olfactory neuroblastoma:the University of Erlangen-Nurenberg experience 1975–2000. Otolaryngol Head Neck Surg 2004, 130:567–574.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Klepin, H.D., McMullen, K.P. & Lesser, G.J. Esthesioneuroblastoma. Curr. Treat. Options in Oncol. 6, 509–518 (2005). https://doi.org/10.1007/s11864-005-0029-7
Issue Date:
DOI: https://doi.org/10.1007/s11864-005-0029-7